Prognostic and Predictive Role of Intrinsic Molecular Subtypes in BRCA-associated Breast Cancer

Plain-language summary

This study investigates the role of intrinsic molecular subtypes in predicting prognosis and treatment response in breast cancer patients who carry a BRCA1 or BRCA2 gene variant. Patients aged 18 and over who carry a pathogenic germline variant in BRCA1 or BRCA2 and have HR+/HER2-negative breast cancer may take part. This is a study with no assigned phase and it is currently recruiting participants.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Recruiting

Sponsor

Angela Toss

Start date

9/5/2024

Estimated completion

12/1/2026

Countries

Italy

Related genes

Locations

• Genova, Italy
• Milan, Italy
• Milan, Italy
• Modena, Italy
• Padova, Italy
• Roma, Italy

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria:

* Age 18 years or older
* Patients carrying a pathogenic or likely pathogenic germline variant in BRCA1 or BRCA2 with a histologically confirmed diagnosis of HR+/HER2-negative breast cancer
* Patients with available hospital and/or outpatient medical records for clinical data collection
* Presence of available formally fixed paraffin-embedded (FFPE) breast tumor tissue (primary or metastatic site)

Exclusion Criteria:

* None